LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) reported 2024 financial and operational results on February 26 th , producing sales of over $1 billion for Pylarify during ...

Lantheus Holdings Inc (($LNTH)) has held its Q4 earnings call. Read on for the main highlights of the call. Lantheus Holdings Inc. recently held ...

Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.

Q4 2024 Earnings Call Transcript February 26, 2025 Operator: Good morning. Welcome to the Lantheus Fourth Quarter and Full ...

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Lantheus (LNTH – Research Report), with a price ...

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session after the company ...

Lantheus Holdings shares rose after its adjusted earnings for the fourth quarter and 2025 outlook estimates were higher than expected. The stock climbed 20%, to $96.36. The stock has gained about half ...

Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors section of the company's ...

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q4 CY2024 results topping the market’s revenue ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

Lantheus Holdings expects full-year earnings in the range of $7 to $7.20 per share, with revenue in the range of $1.55 billion to $1.61 billion. This story was generated by Automated Insights ( http:/ ...

Principal Financial Group Inc. reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 22.7% during the 4th quarter, according to the company in its most recent 13F ...